undamentalytics Newsletter
Sign in

Recursion Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2025, Recursion Pharmaceuticals, Inc. had total assets of $1.47bn, total liabilities of $343m and shareholders' equity of $1.13bn. It held $743m in cash against $18.7m of debt: net cash of $725m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents75262285550392594743550
Receivables—000————
Total current assets—266535570438714813616
Goodwill—11152149162161
Total assets—2996107016541,4491,4741,222
Accounts payable—1354221816
Deferred revenue (current)—10105736623816
Total current liabilities—234710093187148123
Long-term debt—1111119100
Total debt012111271912
Total liabilities—5767215190414343316
Shareholders' equity−124−2065434864631,0351,131906
Non-controlling interests and other (assets − liabilities − equity)—448——————
Net debt (negative = net cash)−75−250−284−549−390−567−725−538
Shares outstanding—22m—191m234m—528m561m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CYTK vs RXRXABCL vs RXRXRXRX vs WVERXRX vs VRDN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Recursion Pharmaceuticals, Inc.